GW Henssler & Associates Ltd. Sells 1,739 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

GW Henssler & Associates Ltd. lowered its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 0.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 199,765 shares of the medical equipment provider’s stock after selling 1,739 shares during the period. Zimmer Biomet makes up approximately 1.3% of GW Henssler & Associates Ltd.’s portfolio, making the stock its 29th largest position. GW Henssler & Associates Ltd.’s holdings in Zimmer Biomet were worth $21,565,000 at the end of the most recent quarter.

A number of other hedge funds also recently added to or reduced their stakes in the company. Dunhill Financial LLC increased its holdings in shares of Zimmer Biomet by 1,090.0% in the 3rd quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock worth $26,000 after purchasing an additional 218 shares in the last quarter. Ashton Thomas Securities LLC bought a new stake in Zimmer Biomet in the 3rd quarter worth about $28,000. Bangor Savings Bank bought a new stake in Zimmer Biomet in the 3rd quarter worth about $31,000. Brooklyn Investment Group bought a new position in Zimmer Biomet during the 3rd quarter valued at about $35,000. Finally, R Squared Ltd bought a new position in Zimmer Biomet during the 4th quarter valued at about $63,000. 88.89% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts have recently weighed in on ZBH shares. Royal Bank of Canada boosted their price objective on shares of Zimmer Biomet from $120.00 to $125.00 and gave the company an “outperform” rating in a report on Monday, November 4th. Stifel Nicolaus boosted their target price on shares of Zimmer Biomet from $130.00 to $138.00 and gave the company a “buy” rating in a research note on Thursday, January 23rd. JPMorgan Chase & Co. upgraded Zimmer Biomet from a “neutral” rating to an “overweight” rating and raised their price target for the stock from $125.00 to $128.00 in a research note on Tuesday, December 17th. Barclays reduced their price objective on Zimmer Biomet from $125.00 to $118.00 and set an “underweight” rating for the company in a research report on Thursday, December 12th. Finally, Oppenheimer dropped their target price on Zimmer Biomet from $145.00 to $135.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 15th. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have given a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $124.11.

Zimmer Biomet Trading Down 1.1 %

Shares of Zimmer Biomet stock opened at $109.36 on Monday. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $100.67 and a fifty-two week high of $133.90. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.70 and a current ratio of 1.36. The company has a market capitalization of $21.77 billion, a P/E ratio of 20.79, a P/E/G ratio of 1.88 and a beta of 1.02. The company has a fifty day moving average of $107.94 and a 200 day moving average of $108.26.

Zimmer Biomet Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, January 31st. Shareholders of record on Monday, December 30th were paid a $0.24 dividend. The ex-dividend date was Monday, December 30th. This represents a $0.96 annualized dividend and a yield of 0.88%. Zimmer Biomet’s payout ratio is 18.25%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.